Listenberger. VACM-1, a cullin gene family member, regulates cellular signaling. Am J Physiol Cell Physiol 279: C266-C273, 2000.-Vasopressin-activated Ca 2ϩ -mobilizing (VACM-1) receptor binds arginine vasopressin (AVP) but does not have amino acid sequence homology with the traditional AVP receptors. VACM-1, however, is homologous with a newly discovered cullin family of proteins that has been implicated in the regulation of cell cycle through the ubiquitin-mediated degradation of cyclin-dependent kinase inhibitors. Because cell cycle processes can be regulated by the transmembrane signal transduction systems, the effects of VACM-1 expression on the Ca 2ϩ and cAMP-dependent signaling pathway were examined in a stable cell line expressing VACM-1 in VACM-1 transfected COS-1 cells and in cells cotransfected with VACM-1 and the adenylyl cyclase-linked V 2 AVP receptor cDNAs. Expression of the VACM-1 gene reduced basal as well as forskolin-and AVP-stimulated cAMP production. In cells cotransfected with VACM-1 and the V 2 receptor, the AVP-and forskolin-induced increases in adenylyl cyclase activity and cAMP production were inhibited. The inhibitory effect of VACM-1 on cAMP production could be reversed by pretreating cells with staurosporin, a protein kinase A (PKA) inhibitor, or by mutating S730A, the PKA-dependent phosphorylation site in the VACM-1 sequence. The protein kinase C specific inhibitor Gö-6983 further enhanced the inhibitory effect of VACM-1 on AVPstimulated cAMP production. Finally, AVP stimulated D-myo-inositol 1,4,5-trisphosphate production both in the transiently transfected COS-1 cells and in the stable cell line expressing VACM-1, but not in the control COS-1 and Chinese hamster ovary cells. Our data demonstrate that VACM-1, the first mammalian cullin protein to be characterized, is involved in the regulation of signaling. adenylyl cyclase; adenosine 3Ј,5Ј-cyclic monophosphate; protein kinase A; protein kinase C; D-myo-inositol 1,4,5-trisphosphate VASOPRESSIN-ACTIVATED CALCIUM-MOBILIZING (VACM-1) receptor is a 780-amino acid protein originally cloned from a rabbit medullary cDNA library (7). Expression of the cloned VACM-1 protein in COS-1 cells results in increased arginine vasopressin (AVP) binding (dissociation constant of about 2 nM) and in increased AVP-dependent mobilization of cytosolic-free Ca 2ϩ (7). -Phe-Ile-Asn-Cys-Pro-Arg-OH, which differs structurally from the DDAVP, can be detected (7). The immunohistochemistry and immunoprecipitation studies using polyclonal antibodies prepared against a synthetic peptide derived from the NH 2 -terminal sequence of VACM-1 indicate that the VACM-1 receptor is a cell membrane protein (7). Importantly, however, VACM-1 does not share any structural or sequence homology with the cloned V 1 and V 2 receptors (7). Consequently, we concluded that the VACM-1 receptor differs from the pharmacologically defined V 1 and V 2 receptors and may represent a novel receptor for AVP or a receptor for an as yet unidentified peptide similar in structure to AVP (7). The biological role of the VACM-1 receptor is yet to be defined.
adenylyl cyclase; adenosine 3Ј,5Ј-cyclic monophosphate; protein kinase A; protein kinase C; D-myo-inositol 1,4,5-trisphosphate VASOPRESSIN-ACTIVATED CALCIUM-MOBILIZING (VACM-1) receptor is a 780-amino acid protein originally cloned from a rabbit medullary cDNA library (7) . Expression of the cloned VACM-1 protein in COS-1 cells results in increased arginine vasopressin (AVP) binding (dissociation constant of about 2 nM) and in increased AVP-dependent mobilization of cytosolic-free Ca 2ϩ (7) . -Phe-Ile-Asn-Cys-Pro-Arg-OH, which differs structurally from the DDAVP, can be detected (7) . The immunohistochemistry and immunoprecipitation studies using polyclonal antibodies prepared against a synthetic peptide derived from the NH 2 -terminal sequence of VACM-1 indicate that the VACM-1 receptor is a cell membrane protein (7) . Importantly, however, VACM-1 does not share any structural or sequence homology with the cloned V 1 and V 2 receptors (7). Consequently, we concluded that the VACM-1 receptor differs from the pharmacologically defined V 1 and V 2 receptors and may represent a novel receptor for AVP or a receptor for an as yet unidentified peptide similar in structure to AVP (7) . The biological role of the VACM-1 receptor is yet to be defined.
Interestingly, the human homologue of the VACM-1 receptor, identified by Byrd and co-workers (8) , is a highly conserved protein, differing in only seven amino acids from the rabbit VACM-1 protein. The human VACM-1 gene was localized on chromosome 11q22-23 to a region close to the gene for ataxia telangiectasia and was previously associated with a loss of heterozygosity in breast cancer tumor samples (8) . Because of the proximity of the VACM-1 gene to this region, and its sequence homology with a recently identified gene family termed cullins, which in yeast and nematodes regulate cell cycle transitions (18, 20) , Byrd et al. (8) suggested that VACM-1 may be a possible tumor suppressor gene.
To date, six cullin genes have been identified in Homo sapiens, five in Caenorhabditis elegans, and three in Saccharomyces cervisiae (18, 20) . Their biological role is not fully understood and may be rather diverse. For example, in C. elegans, cul-1 is required for developmentally programmed transition from G 1 to the G 0 phase (18) , whereas its yeast homologue, cDc53, targets phosphorylated G 1 cyclins for degradation via the ubiquitin-dependent pathway (20) . Hs-cul-2 has been implicated in the tumor-suppressor activity of the von Hippel-Lindau gene product (22) , and the expression of Hs-cul-3 and Hs-cul-4 is increased in cultured colon cancer cells (13) and in primary breast cancer cells (10) , respectively. The biological function of cul-5, which shares 96% sequence homology with VACM-1 (157/163 amino acids at their COOH terminus), remains unknown.
In an attempt to further characterize the VACM-1 receptor and to elucidate the significance of its link to both the V 1 AVP receptor and to cullins, we have recently examined its tissue expression at the mRNA and at the protein level. Whereas Northern blot and RT-PCR analyses indicated that VACM-1 mRNA may be present in numerous tissues (5, 7, 8) , the immunostaining of tissue sections with polyclonal antibodies prepared against synthetic peptides derived from the sequence of VACM-1 indicates that the VACM-1 receptor is expressed specifically in the vascular endothelial cells. In the kidney, it is also present in the medullary collecting tubule cells (5) . Because those structures are well recognized for their role in controlling fluid homeostasis, we have speculated that VACM-1 may be involved in the regulation of vascular endothelial cells and the collecting tubule permeability (5) .
The peptide hormone AVP is an effective vasoconstrictor, regulates cell permeability (14, 16) , and is recognized as a growth factor that can affect cell proliferation and tissue regeneration (24, 28) . These diverse effects of AVP involve either the cAMP-or the Ca 2ϩ -signaling pathways (6, 14, 16, 28) . We were thus intrigued by the possibility that VACM-1 may be involved in the regulation of these signaling pathways. The work reported here shows that VACM-1, when expressed in vitro, significantly reduces AVP-and forskolin (FSK)-stimulated adenylyl cyclase activity and cAMP production and increases AVP-dependent D-myo-inositol 1,4,5-trisphosphate (IP 3 ) production. The mammalian VACM-1 receptor, therefore, may represent a unique protein involved in the regulation of cell signaling. cAMP measurements. Cells were incubated with various doses of effectors or vehicle (simplified saline solution, SSS) (5, 6) for 10 min. After the treatment, the reaction was stopped with ice-cold 12% TCA, and cells were frozen at Ϫ80°C. Cells were then centrifuged for 15-20 min, and the supernatant was separated for measurements of cAMP. cAMP production was analyzed either in duplicate or in triplicate using either a 125 I-cAMP RIA (5, 6) or a nonradioactive cAMP kit from Amersham (Arlington Heights, IL).
MATERIALS AND METHODS

Materials
Adenylyl cyclase activity. Adenylyl cyclase activity was assayed in quadruplicate as described by Birnbaumer and Yang (4) . Briefly, cells grown and treated as described above were rinsed with Tris-buffered saline (10 mM Tris ⅐ HCl, 150 mM NaCl, pH 7.4) and incubated for 2 h in 50 ml of solution containing 0.1 mM [␣-32 P]ATP, 2 mM MgCl, 10 mM GTP, 1 mM EDTA, 1 mM cAMP, 2 mM methyl isobutyl xanthine, 50 mg/ml saponin, 20 mM creatinine phosphate, 20 mg/ml creatinine phosphokinase, 20 mg/ml myokinase, and 5 mM p-nitrophenyl phosphate. [ 3 H]cAMP (10,000 cpm/well) was added for determination of cAMP recovery. The reaction was stopped by adding 40 mM ATP, 10 mM cAMP, and 1% SDS solution. The relative number of cells per well was determined by measuring the hydrolysis of p-nitrophenyl phosphate (A405). cAMP was isolated by chromatography on Dowex 50-XB and Alumina columns. Eluates were collected in scintillation vials and quantitated by scintillation counting.
IP 3 measurement. IP 3 was measured using the assay by Berridge (3) as described previously (6) . Briefly, cells were incubated for 6 h with 15 Ci of myo-[ 3 H]inositol at 37°C and exposed to either AVP (10 Ϫ6 M) or vehicle (SSS) for 10 min. For some assays, 10 g/ml of pertussis toxin was added to the incubation medium. After the 6-h incubation with pertussis toxin or vehicle, and after the treatment with AVP, the reaction was stopped with ice-cold 12% TCA, and cells were put on a shaker for 15 min to disrupt the membranes. Cells were then centrifuged for 15-20 min, and the supernatant was separated for measurements of inositol phosphates using AG-1X8 resin columns (Bio-Rad Laboratories). Inositol 1-phosphate was eluted with 200 mM ammonium formate/ 100 mM formic acid, D-myo-inositol 1,4-bisphosphate with 400 mM ammonium formate/100 mM formic acid, and IP 3 with 1 M ammonium formate/100 mM formic acid. The pellet was resuspended in 0.5 ml of 1 mM KCl, 10 mM myo-inositol, and 0.5 ml of chloroform for total lipid measurements. The results were calculated as counts per minute of Measurement of Ca 2ϩ mobilization. Intracellular concentrations of free Ca 2ϩ in COS-1 cells were measured spectrophotometrically with an AB2 dual-excitation spectrofluorometer (SLM-Aminco) using fura 2-AM as a Ca 2ϩ indicator as described previously (7) . However, to sufficiently load Chinese hamster ovary (CHO) and stably VACM-1 transfected CHO cells (clone 1) with fura 2-AM, cells were incubated with 4 M fura 2-AM in the presence of 12.5 M sulfinpyrazone, a potent inhibitor of organic anion transport, 1% FBS, and 50 M sucrose at room temperature for 60 to 90 min (19) . In the absence of sulfinpyrazone, we could not detect any responses to either AVP or ionomycin. Cells were washed two times with 5 ml of SSS, centrifuged, resuspended in 300 l of SSS, and used in measurements of Ca 2ϩ concentration. Site-directed mutagenesis. Site-directed mutagenesis was performed using a QuickChange site-directed mutagenesis kit from Stratagene (La Jolla, CA). The mutagenesis primers were synthesized by Sigma-Genosys (Woodland, TX), and the mutation site sequences were confirmed by sequencing performed by Sequi-net (Colorado State Univ., Ft. Collins, CO). The altered nucleotide sequences are underlined. S720A mutation primers were: forward, 5ЈGAG AAA GAA AAT TGC TAA TGC TCA ACT GCA GAC TG3Ј, reverse: 5ЈCAG TCT GCA GTT GAG CAT TAG CAA TTT TCT TTC TC3Ј. The T325A mutation primers were: forward, 5ЈCCA AGA GCA CTT CTT TAA GCT TTG CTT CAA TCT CTT CAG AAG CAA GCT TTT TG3Ј, reverse: 5ЈGCA AAA AGC TTG CTT CTG AAG AGA TTG AAG CAA AGC TTA AAG AAG TGC TCT TGG3Ј.
Statistical analysis. Data are expressed as means ϩ one SE of the mean. As appropriate, either ANOVA or a paired Student's t-test was used for data analysis. Significance was set at P Ͻ 0.05.
RESULTS
We found that the expression of VACM-1 cDNA in COS-1 cells reduces basal cAMP production and inhibits isoproterenol (IP, 10 Ϫ8 M)-and FSK (10 Ϫ4 M)-induced increases in cAMP (Fig. 1A) . These results were similar using either a 125 I-RIA or a nonradioactive kit to measure cAMP production. Similarly, in clone 1 cells in stably expressing VACM-1, the basal and FSK-induced increase in cAMP production was attenuated compared with that in the control CHO cells (Fig. 1B) . Finally, 10
Ϫ6 M AVP induced a significant increase in cAMP production in CHO cells transfected with the V 2 cDNA, but did not affect cAMP production in clone 1 cells transfected with the V 2 cDNA (Fig. 1C) .
To confirm the direct involvement of adenylyl cyclase in the VACM-1-dependent regulation of cAMP production, the enzyme activity was assessed directly. Our data, shown in Fig. 2A , indicate that a dose-dependent stimulation of adenylyl cyclase activity by FSK in CHO cells was largely absent in clone 1 cells. Only at 100 M FSK was a small increase in adenylyl cyclase activity observed. Similarly, AVP increased adenylyl cyclase activity in CHO cells transfected with the V 2 receptor, but not in clone 1 cells transfected with the V 2 receptor (Fig. 2B) . To confirm these VACM-1-dependent changes in adenylyl cyclase activity, the above experiments were repeated in COS-1 cells transiently transfected with VACM-1 cDNA, V 2 cDNA, or VACM-1 and V 2 cDNAs. As shown in Fig. 2C , the effects of FSK and AVP were significantly attenuated in cells expressing VACM-1 but not in mock transfected COS-1 cells.
To examine a potential role of protein kinase A (PKA) and protein kinase C (PKC) in the VACM-1-dependent regulation of cAMP production, we tested the effects of their inhibitors, staurosporin and Gö-6983, respectively. Although staurosporin has been used in the micromolar range to inhibit both enzymes in vitro (15, 23) , its established 50% inhibitory concentration (IC 50 ) for PKC and PKA is 0.7 nM and 7 nM, respectively. Consequently, the effects of 0.7, 10, and 500 nM staurosporin were tested in this study. Our data indicate that 0.7 nM staurosporin had little effect on VACM-1-inhibited AVP-dependent cAMP production (Fig. 3A, group 3) . The effect of 10 nM staurosporin was tested on two independent cell preparations. As previously, in the absence of staurosporin, AVP increased cAMP production by 275% in control cells transfected with the V 2 cDNA and by 156% in the V 2 and VACM-1 cDNA cotransfected cells (n ϭ 2). In cells pretreated with 10 nM staurosporin, AVP increased cAMP production by 221% in control cells expressing the V 2 receptor and by only 183% in cells cotransfected with the V 2 and VACM-1 cDNAs (n ϭ 2). In cells treated with 500 nM staurosporin, VACM-1 expression no longer attenuated the AVP-increased cAMP concentration (Fig. 3A, group 4) . To ascertain the specificity of VACM-1 RECEPTOR REGULATES CELLULAR SIGNALING this action, the effect of 500 nM staurosporin on basal cAMP production was tested (n ϭ 2). As before, in the absence of staurosporin, AVP increased cAMP concentration by 280% in the V 2 transfected cells and by 175% in the V 2 and VACM-1 cDNA transfected cells. In the same cell cultures pretreated with 500 nM staurosporin, AVP increased cAMP concentration by 300% in control cells transfected with the V 2 receptor only and by 600% in the V 2 and VACM-1 cDNA cotransfected cells. To confirm the specificity of the PKA-dependent action of VACM-1, the effects of AVP were examined in cells cotransfected with the V 2 receptor and with VACM-1 cDNA that had the PKA-dependent phosphorylation sites S720 and T325 (5) mutated to alanine. These results (summarized in Fig. 3 , groups 7 and 8, respectively) indicate that S730A but not T325A mutation of the PKA-dependent phosphorylation sites in VACM-1 cDNA completely reverses the attenuating effect of VACM-1 on AVP-dependent cAMP production. Finally, we examined the effect of the PKC-specific inhibitor Gö-6983 (IC 50 : for PKC␣ and PKC␤, 7 nM; for PKC␥, 10 nM; and for PKC, 60 nM) on AVP-dependent cAMP production in the V 2 and VACM-1 cDNA cotransfected cells. As shown in Fig. 3A , groups 5 and 7, both 7 nM and 700 nM Gö-6983 enhanced the inhibitory effect of VACM-1 on AVP-stimulated cAMP production. The effects of staurosporin, Gö-6983, and mutagenesis of PKA-specific phosphorylation sites in VACM-1 cDNA on FSK-dependent regulation of cAMP production in the V 2 receptor cDNA transfected cells and in V 2 and VACM-1 cDNA cotransfected cells are summarized in Fig. 3B . At 0.7 nM, staurosporin further enhanced the inhibitory effect of VACM-1 on cAMP levels (Fig. 3B, group 3 vs. group 2) . At 10 nM staurosporin, the inhibitory effect of VACM-1 cDNA on FSK-induced increase in cAMP concentration was attenuated (n ϭ 2, data not shown). Pretreatment of cells with 500 nM staurosporin reversed the inhibitory effect of VACM-1 protein expression on FSK-induced change in cAMP levels (group 4). Mutation of S720A or T325A in the VACM-1 sequence did not have a clear effect on the FSK-induced changes in cAMP production (Fig. 3B , groups 7 and 8) because these changes were no longer significantly different from either the control (group 1) or VACM-1 transfected cells (group 2). Finally, 7 nM Gö-6983 further enhanced the inhibitory effect of VACM-1 on FSK-induced changes in cAMP production (Fig. 3B, group 5) . At 700 nM, Gö-6983 reversed the inhibitory effect of VACM-1 on FSK-dependent cAMP production (Fig. 3B, group 6) .
To examine the mechanism by which AVP induces VACM-1-dependent changes in Ca 2ϩ (5) , the effects of AVP on IP 3 production were measured in stably transfected CHO cells (clone 1) and in transiently transfected COS-1 cells. As shown in Fig. 4A, 10 Ϫ6 M AVP treatment had no significant effect on IP 3 production in the untransfected CHO cells (n ϭ 5). The effect of AVP on IP 3 production in the stable cell line (clone 1) was most pronounced at 1.5 min (n ϭ 5, P Ͻ 0.05, compared with the time 0 or with the control CHO cells). A pretreatment of clone 1 cells with 10 g/ml pertussis toxin for 6 h inhibited the AVP-induced increase in IP 3 production (Fig. 4A, n ϭ 5) . The effect of AVP on IP 3 production was associated with changes in the cytosolic-free Ca 2ϩ concentration (Fig. 4A, inset) . Similarly, AVP significantly increased IP 3 production in COS-1 cells transfected with VACM-1 cDNA but not in shamtransfected COS-1 cells (Fig. 4B) . This effect of AVP on IP 3 production in cells transfected with VACM-1 was comparable to its well-documented effect in A7r5 and in 3T3 cell lines (data not shown).
DISCUSSION
This study demonstrates that IP 3 and cAMP-signaling pathways, affected by G protein-linked ligands that include AVP and by growth-regulating factors (2, 11, 13, 24, 28) , are altered in cells that express VACM-1 protein. Both stable and transient expression of VACM-1 confers upon cells the ability to inhibit cAMP production (Fig. 1) . The inhibitory effect of VACM-1 expression on cAMP production is associated with decreased adenylyl cyclase activity (Fig. 2) . Further, in cells expressing VACM-1, AVP treatment increases IP 3 production (Fig. 4) that may be responsible for the subsequent increase in Ca 2ϩ (5) . These opposite effects on the two signaling pathways indicate that the inhibitory action of VACM-1 on cAMP synthesis is specific and not due to a general downregulation of signaling pathways. The inhibitory effect of VACM-1 may be dependent on the levels of VACM-1 expressed (data not shown) and can be overcome by a high concentration of AVP (Fig. 2B) . The observation that VACM-1 may also affect the isoproterenol-dependent cAMP production (Fig. 1A) suggests that these attenuating effects of VACM-1 protein may not be limited to the action of AVP. Whether the expression of VACM-1 affects other types of membrane receptors remains to be elucidated. Finally, the inhibitory action of VACM-1 expression on the FSK-dependent adenylyl cyclase activity and cAMP production suggests that this effect may even be independent of the ligand binding.
Although the cellular mechanism of the downregulating effect of VACM-1 protein on adenylyl cylcase activity is not clear, the ability of VACM-1 to attenuate the AVP and FSK-induced production of cAMP appears to depend on its phosphorylation status by PKA and PKC. Staurosporin, at doses that inhibit PKA activity, either attenuated or reversed the VACM-1-dependent decrease in cAMP production in response to AVP and to FSK. Although staurosporin's established IC 50 for PKC and PKA is 0.7 nM and 7 nM, respectively, at high concentrations, it can be a general kinase inhibitor (15, 23) . Consequently, its PKA specificity described here could be questioned. We therefore reexamined the responses to AVP and FSK in cells expressing the V 2 receptor and cotransfected with VACM-1 cDNA with its two putative PKA phosphorylation sites, S730 and T325 (5), mutated to alanine. Elimination of the S730 but not the T325 PKA phosphorylation site of VACM-1 resulted in a complete inhibition of the VACM-1 activity, thus suggesting a direct effect of PKA on the VACM-1 receptor. Unlike staurosporin, PKC inhibitor Gö-6893, regardless of its concentration, further enhanced VACM-1-dependent downregulation of AVPinduced changes in cAMP concentration. However, the effect of the S730A mutation on the FSK-dependent regulation of cAMP is less clear. Although the inhibitory effect of VACM-1 in those experiments was attenuated, the differences were not statistically significant when compared with either the control cells or with cells cotransfected with the wild-type VACM-1 cDNA. Similarly, Gö-6893, at a concentration close to its IC 50 for PKC␣ and PKC␤ (7 nM), enhanced the attenuating effect of VACM-1 on the FSK-induced changes in cAMP production. The attenuating effect of VACM-1 on the FSK-induced changes in cAMP, however, was reversed with high concentrations of the PKC inhibitor. Although the reasons for these differences are not clear, it is possible that at high doses, Gö-6893 also inhibits PKA activity. It is also possible that the sensitivity of the AVP-and FSK-regulated pathways to VACM-1 varies, or that only specific isoforms of adenylyl cyclase are regulated by VACM-1. So far, nine mammalian isoforms of the enzyme have been identified, cloned, and shown to differ in their responses to regulatory molecules and in their tissue specificity (17, 25, 26) . Whereas all adenylyl cyclase subtypes can be stimulated by G s ␣ and by FSK, only some can be stimulated by Ca 2ϩ calmodulin, and some are inhibited by G i , Ca 2ϩ , and PKA. Some cyclases can also be regulated by the ␤␥-subunits of the G protein and by PKC (25, 26) . For example, isoforms I, III, and VII can be stimulated by Ca 2ϩ calmodulin and G s ␣, isoforms IV and VII by G s ␣ and G␤␥, and isoforms V and VI can be inhibited by G i ␣ and Ca 2ϩ (21, 25, 26) . In the kidney, where VACM-1 expression is specific to the collecting tubule and to vascular endothelial cells, types IV, V, VI, VII, and IX of adenylyl cyclase have been identified (25) . The isoforms of adenylyl cyclase expressed by either the CHO or the COS-1 cells used here have not yet been identified. Consequently, it remains to be elucidated whether the attenuating effect of VACM-1 expression on cAMP production is specific to a particular isoform of adenylyl cyclase or is limited by the type expressed in the system where it is studied.
Another level of complexity within the adenylyl cyclase signaling system is presented by the modulatory activity of the G proteins that can further differentiate the adenylyl cyclase-dependent signaling systems. For example, different combinations of the isoforms of the G␤␥ have an opposite effect on the same adenylyl cyclase isoforms (1) . Whether these modulatory proteins are also involved in the action of VACM-1 described above is not apparent from our studies. Whereas the V 2 receptor-dependent stimulation of adenylyl cyclase by AVP involves the activation of the G s ␣, VACM-1 shares pharmacological characteristics with the V 1 receptors (5) that are coupled to the G q/11 , and in some instances, to the G i protein (29) . Our previous work suggested that the effects of purine and pyrimidine nucleotides on binding of AVP to membranes from COS-1 cells transfected with VACM-1 cDNA were inconsistent with the typical selective effects of GDP and GTP on binding of ligands to G protein-linked receptors (5) . However, the presence of a G protein-binding consensus sequence in VACM-1 (5, 21) and reports that PKC inhibits AVP-stimulated cAMP accumulation via a G i -dependent mechanism (27) have led us to examine potential involvement of a pertussis toxin-sensitive G protein in the VACM-1 signaling. Our data suggest that pretreatment of cells expressing VACM-1 with pertussis toxin for 6 h inhibits IP 3 production (Fig. 4) but does not appear to reverse the inhibitory effect of VACM-1 on the AVP-or FSK-regulated cAMP production (data not shown). Consequently, the possibility that the VACM-1-depen-dent action on adenylyl cyclase activity involves G protein remains to be determined.
Although VACM-1 has been identified as a vasopressin (AVP) binding receptor, it does not share any structure or sequence homology with the AVP receptors. Further, AVP-binding characteristics of VACM-1 protein and its tissue distribution do not match that of the V 1 or the V 2 AVP receptors (5, 7) . Consequently, the relevance of its specific expression in the collecting tubule and in endothelial cells to the well-established biological effects of AVP in those structures remains unclear. Similarly unclear is the significance of its high sequence homology with recently identified cullins. Unlike cullins, which are either nuclear or cytosolic proteins (18, 22) , VACM-1 expression localizes to the cell membrane (6, 7) . Also, unlike cullins that appear to be rather ubiquitous (18) , VACM-1 protein is expressed primarily in the vascular endothelial cells and in the renal collecting tubule cells (5) . Finally, the function of cul-5, which shares highest sequence homology with VACM-1 (96% identity in the last 153/168 amino acids), has not been determined to date. Because the highest sequence homology between cullins and VACM-1 is observed in their COOH-terminal sequence, whereas the putative transmembrane region has been identified at the NH 2 -terminal of VACM-1 (amino acids 259-279), it is possible that VACM-1-related proteins lacking the transmembrane region may exist.
In summary, VACM-1, which is specifically expressed in the vascular endothelial cells and renal collecting tubule cells (5), when expressed in vitro, attenuates cAMP-dependent signal transduction. Further, the biological activity of VACM-1 may depend on its phosphorylation status maintained by PKA and PKC activities. Because VACM-1 shares high sequence homology with cullin proteins that regulate cell cycle, these data suggest an additional role for this largely uncharacterized multigene family.
